Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Picozzi · SciRah

Researcher profile · Semantic Scholar

V. Picozzi

Share profile

V. Picozzi — researcher profile on SciRah

h-index: 32
Works: 179
Citations: 6,264

Most-cited papers

Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.
A. Bardia, W. Messersmith, E. Kio, J. Berlin +19 more
2021Annals of Oncology389 citations Open access
Semantic Scholar
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
A. Ocean, A. Starodub, A. Bardia, L. Vahdat +10 more
2017Cancer226 citations Open access
Semantic Scholar
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
D. Le, V. Picozzi, Andrew H. Ko, Z. Wainberg +19 more
2019Clinical Cancer Research202 citations Open access
Semantic Scholar
Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
M. Pishvaian, R. J. Bender, D. Halverson, L. Rahib +12 more
2018Clinical Cancer Research189 citations Open access
Semantic Scholar
Pancreas Cancer‐Associated Weight Loss
A. Hendifar, Maria Q. B. Petzel, T. Zimmers, C. Denlinger +3 more
2018The Oncologist153 citations Open access
Semantic Scholar
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Z. Hu, J. Bendell, A. Bullock, N. Loconte +18 more
2019Cancer Medicine78 citations Open access
Semantic Scholar
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
V. Picozzi, Adnan A. Alseidi, J. Winter, M. Pishvaian +9 more
2020ESMO Open72 citations Open access
Semantic Scholar
A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
M. Pishvaian, R. J. Bender, L. Matrisian, L. Rahib +12 more
2016OncoTarget72 citations Open access
Semantic Scholar
Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
D. Le, Andrew H. Ko, Z. Wainberg, V. Picozzi +16 more
201748 citations
Semantic Scholar
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
E. O'Reilly, V. Sahai, J. Bendell, A. Bullock +16 more
201743 citations
Semantic Scholar
Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop
José M. García, R. Dunne, K. Santiago, Lisa Martin +10 more
2022Journal of Cachexia, Sarcopenia and Muscle31 citations Open access
Semantic Scholar
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
Marc T. Roth, D. Cardin, E. Borazanci, Margaux A. Steinbach +5 more
2020The Oncologist31 citations Open access
Semantic Scholar
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours
G. Brar, E. Blais, R. J. Bender, J. Brody +11 more
2019British Journal of Cancer29 citations Open access
Semantic Scholar
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
V. Picozzi, R. Ramanathan, M. Lowery, A. Ocean +27 more
2015European Journal of Cancer28 citations Open access
Semantic Scholar
Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer
V. Picozzi, S. Narayanan, X. Hu, J. Vacirca
2017Journal of Gastrointestinal Cancer26 citations
Semantic Scholar
Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol
F. Rocha, Yashushi Hashimoto, L. Traverso, Russell K. Dorer +3 more
2016Annals of Surgery24 citations
Semantic Scholar
Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy
Hong Peng, Ru Chen, T. Brentnall, J. Eng +2 more
2019Clinical Proteomics20 citations Open access
Semantic Scholar
Management of Patients With Pancreatic Cancer Using the “Right Track” Model
A. Rosenzweig, J. Berlin, S. Chari, H. Kindler +7 more
2023The Oncologist17 citations Open access
Semantic Scholar
Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.
V. Picozzi, M. Pishvaian, K. Mody, J. Winter +9 more
201817 citations
Semantic Scholar
Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).
K. Lim, K. Spencer, Rachael A Safyan, V. Picozzi +10 more
2024Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
V. Picozzi, F. Rocha, S. Helton, M. Pishvaian +12 more
201712 citations
Semantic Scholar
A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
V. Sahai, M. Saif, A. Kalyan, P. Philip +8 more
2019Journal of Pancreatic Cancer11 citations Open access
Semantic Scholar
Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience.
Stephen Y. Oh, A. Edwards, M. Mandelson, H. Hahn +6 more
2017American Journal of Surgery11 citations
Semantic Scholar
Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan (FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing
Smita S. Joshi, D. Catenacci, T. Karrison, Jaclyn D Peterson +11 more
2019Clinical Cancer Research10 citations Open access
Semantic Scholar
FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
V. Picozzi, J. Pipas, A. Koong, A. Giaccia +14 more
201610 citations
Semantic Scholar
Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?
J. Clanton, Stephen Y. Oh, Stephen J. Kaplan, E. Johnson +9 more
2018HPB9 citations Open access
Semantic Scholar
Resected pancreatic cancer (PC): Impact of adjuvant therapy (Rx) at a high-volume center (HVC) on overall survival (OS).
M. Mandelson, V. Picozzi
20169 citations
Semantic Scholar
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Z. Kanji, A. Edwards, M. Mandelson, Nadav Sahar +9 more
2018Annals of Surgical Oncology8 citations
Semantic Scholar
Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).
V. Picozzi, A. Duliege, E. Collisson, A. Maitra +10 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond
M. Noel, Semmie Kim, Marion L Hartley, S. Wong +8 more
2022Cancer Medicine7 citations Open access
Semantic Scholar
LAPIS: Randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC).
V. Picozzi, K. Khan, P. Hammel, M. Reni +9 more
2025Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
M. Noel, A. Wang-Gillam, A. Ocean, S. Chawla +2 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study.
V. Picozzi, J. Leach, J. Seng, S. Anthony +10 more
20175 citations
Semantic Scholar
Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.
H. Babiker, T. Macarulla, P. Philip, C. Becerra +2 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors
R. Jain, Edward J. Kim, H. Lenz, W. Messersmith +12 more
2021Annals of Oncology4 citations Open access
Semantic Scholar
Abstract PO-050: Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)
V. Picozzi, A. Duliege, A. Maitra, M. Hidalgo +7 more
2021Other Topics4 citations Open access
Semantic Scholar
Phase II/III study of SM-88 in patients with metastatic pancreatic cancer.
V. Chung, S. Chawla, Huan Dong, Semmie Kim +14 more
20214 citations
Semantic Scholar
Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients
A. Ocean, M. Noel, A. Wang-Gillam, S. Chawla +5 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA).
Anitra Engebretson, J. Brody, L. Rahib, L. Matrisian +11 more
20164 citations
Semantic Scholar
Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.
V. Picozzi, A. Varghese, Paul E. Oberstein, M. Hidalgo +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
A phase III trial of tumor-treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3.
V. Picozzi, T. Macarulla, P. Philip, C. Becerra +1 more
20213 citations
Semantic Scholar
Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect
B. Schroeder, M. Mandelson, V. Picozzi
2021Cancers3 citations Open access
Semantic Scholar
Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
R. Sharkey, A. Ocean, A. Starodub, A. Bardia +9 more
20173 citations
Semantic Scholar
1734PDAnti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients
V. Picozzi, M. Pishvaian, K. Mody, J. Winter +6 more
20173 citations Open access
Semantic Scholar
Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative.
M. Pishvaian, J. Brody, L. Matrisian, A. Hendifar +12 more
20163 citations
Semantic Scholar
PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).
V. Picozzi, T. Macarulla, P. Philip, C. Becerra +1 more
20202 citations
Semantic Scholar
Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.
M. Sternlicht, Dongxia Li, Viet-Tam L. Nguyen, Mairead Carney +6 more
20202 citations
Semantic Scholar
SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC).
Marcus Smith Noel, A. Wang-Gillam, A. Ocean, S. Chawla +3 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in 1st line metastatic pancreatic cancer (MPC).
V. Picozzi, B. Lin, M. Mandelson
20182 citations
Semantic Scholar
Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program.
E. Petricoin, R. J. Bender, D. Halverson, L. Rahib +9 more
20182 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Hendifar×11
Invite
A. Hendifar — researcher profile on SciRah
A. Ocean×10
Invite
A. Ocean — researcher profile on SciRah
M. Pishvaian×10
Invite
M. Pishvaian — researcher profile on SciRah
L. Matrisian×10
Invite
L. Matrisian — researcher profile on SciRah

×9

Invite

A. Wang-Gillam — researcher profile on SciRah

Invite

V. Chung — researcher profile on SciRah

Invite

L. Rahib — researcher profile on SciRah

Invite

S. Mikhail — researcher profile on SciRah

Invite

J. Brody — researcher profile on SciRah

Invite

S. Madhavan — researcher profile on SciRah

E. Petricoin×6

Invite

E. Petricoin — researcher profile on SciRah

Invite

F. Rocha — researcher profile on SciRah